Abraxis BioScience

Overview

Abraxis BioScience

industry	Pharmaceutical
founded	in Los Angeles, California‡R1R‡
founder	Dr. Patrick Soon-Shiong
defunct	2010
hq location city	Los Angeles
hq location country	United States
key people	Mr. Rick Click (Chief Information Officer and Global IT Officer) Dr. Nguyen V. Dat Ph.D. (vice president of Clinical Research)
products	Protein-based therapeutics and technologies for treatment of cancer and other critical illnesses
brands	Abraxane
services	Cancer drugs
revenue	US$359 million (2009)‡R2R‡
operating income	US$-113 million (2009)‡R2R‡
net income	US$-104 million (2009)‡R2R‡
assets	US$1.068 billion (2009)‡R2R‡
equity	US$846 million (2009)‡R2R‡
num employees	885 (2009)‡R2R‡
owner	Celgene

Abraxis BioScience was a global biopharmaceutical, and nano-medicine company that developed treatments for critically ill patients. It had over 2000 employees worldwide in 2007. Abraxis's portfolio included the world's first protein-based nanoparticle chemotherapeutic compound, called nab Technology.[3] From this the company developed Abraxane, a treatment for metastatic breast cancer.[4]

In 2010, Abraxis BioScience was acquired by Celgene Corporation.[5]

History

Abraxis was incorporated in 2001 in Los Angeles.[1] It was formerly known as American Pharmaceutical Partners (APP), which as known for its injectable oncology, anti-infective and critical care.

Abraxis BioScience

History

External links

References